These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 31777258

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
    Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G.
    Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
    Wermuth PJ, Jimenez SA.
    PLoS One; 2018 Mar; 13(5):e0196559. PubMed ID: 29718973
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Src as a Therapeutic Target in Biliary Tract Cancer.
    Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.
    Mol Cancer Ther; 2016 Jul; 15(7):1515-24. PubMed ID: 27196758
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
    Messersmith WA, Rajeshkumar NV, Tan AC, Wang XF, Diesl V, Choe SE, Follettie M, Coughlin C, Boschelli F, Garcia-Garcia E, Lopez-Rios F, Jimeno A, Hidalgo M.
    Mol Cancer Ther; 2009 Jun; 8(6):1484-93. PubMed ID: 19509264
    [Abstract] [Full Text] [Related]

  • 10. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
    Liu TT, Yang KX, Yu J, Cao YY, Ren JS, Hao JJ, Pan BQ, Ma S, Yang LY, Cai Y, Wang MR, Zhang Y.
    J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bosutinib.
    Keller G, Schafhausen P, Brümmendorf TH.
    Recent Results Cancer Res; 2010 Aug; 184():119-27. PubMed ID: 20072835
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606.
    Mancini M, Brusa G, Zuffa E, Corrado P, Martinelli G, Grafone T, Barbieri E, Santucci MA.
    Leuk Res; 2007 Jul; 31(7):979-87. PubMed ID: 17129604
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors.
    Beetham H, Griffith BGC, Murina O, Loftus AEP, Parry DA, Temps C, Culley J, Muir M, Unciti-Broceta A, Sims AH, Byron A, Brunton VG.
    Cancer Res; 2022 Feb 15; 82(4):632-647. PubMed ID: 34921014
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor.
    Isfort S, Crysandt M, Gezer D, Koschmieder S, Brümmendorf TH, Wolf D.
    Recent Results Cancer Res; 2018 Feb 15; 212():87-108. PubMed ID: 30069626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.